At the beginning of the main phase of the trial, slow start prophylaxis and on-demand treatment of bleeding episodes with trial product (Turoctocog alfa pegol (N8-GP)) were allowed at the discretion of the investigator and participants parent(s)/ legally acceptable representative (LAR). The N8-GP dose for pre-prophylaxis treatment (except for bleeding episodes) was 60 International unit per kilogram (IU/kg) body weight (within the range of 50-75 IU/kg) to be administered as a single bolus dose intravenously (i.v.) with more than one week between doses (at the discretion of the investigator). Participants who developed FVIII inhibitors in the trial were shifted to ITI treatment.

For prophylaxis treatment, regular N8-GP administration was initiated no later than at the participants age of 24 months, or after 20 EDs on pre-prophylaxis, whatever came first. During the main phase of the trial, participants received prophylaxis with i.v. injections of N8-GP preferably twice weekly, with doses separated by at least 3, and no more than 4, calendar days. Furthermore, it was permissible to start prophylaxis in the main phase with an every 3rd day or once-weekly dosing regimen. The N8-GP dose for prophylaxis treatment was 60 IU/kg (within the range of 50-75 IU/kg) to be administered as a single bolus dose i.v. on each administration day. Participants who developed FVIII inhibitors in the trial were shifted to ITI treatment.

At the beginning of the main phase of the trial, slow start prophylaxis and on-demand treatment of bleeding episodes with trial product (Turoctocog alfa pegol (N8-GP)) were allowed at the discretion of the investigator and participants parent(s)/ legally acceptable representative (LAR). The N8-GP dose for pre-prophylaxis treatment (except for bleeding episodes) was 60 International unit per kilogram (IU/kg) body weight (within the range of 50-75 IU/kg) to be administered as a single bolus dose intravenously (i.v.) with more than one week between doses (at the discretion of the investigator). Participants who developed FVIII inhibitors in the trial were shifted to ITI treatment.

At the beginning of the main phase of the trial, slow start prophylaxis and on-demand treatment of bleeding episodes with trial product (Turoctocog alfa pegol (N8-GP)) were allowed at the discretion of the investigator and participants parent(s)/ legally acceptable representative (LAR). The N8-GP dose for pre-prophylaxis treatment (except for bleeding episodes) was 60 International unit per kilogram (IU/kg) body weight (within the range of 50-75 IU/kg) to be administered as a single bolus dose intravenously (i.v.) with more than one week between doses (at the discretion of the investigator). Participants who developed FVIII inhibitors in the trial were shifted to ITI treatment.

For prophylaxis treatment, regular N8-GP administration was initiated no later than at the participants age of 24 months, or after 20 EDs on pre-prophylaxis, whatever came first. During the main phase of the trial, participants received prophylaxis with i.v. injections of N8-GP preferably twice weekly, with doses separated by at least 3, and no more than 4, calendar days. Furthermore, it was permissible to start prophylaxis in the main phase with an every 3rd day or once-weekly dosing regimen. The N8-GP dose for prophylaxis treatment was 60 IU/kg (within the range of 50-75 IU/kg) to be administered as a single bolus dose i.v. on each administration day. Participants who developed FVIII inhibitors in the trial were shifted to ITI treatment.

For prophylaxis treatment, regular N8-GP administration was initiated no later than at the participants age of 24 months, or after 20 EDs on pre-prophylaxis, whatever came first. During the main phase of the trial, participants received prophylaxis with i.v. injections of N8-GP preferably twice weekly, with doses separated by at least 3, and no more than 4, calendar days. Furthermore, it was permissible to start prophylaxis in the main phase with an every 3rd day or once-weekly dosing regimen. The N8-GP dose for prophylaxis treatment was 60 IU/kg (within the range of 50-75 IU/kg) to be administered as a single bolus dose i.v. on each administration day. Participants who developed FVIII inhibitors in the trial were shifted to ITI treatment.

At the beginning of the main phase of the trial, slow start prophylaxis and on-demand treatment of bleeding episodes with trial product (Turoctocog alfa pegol (N8-GP)) were allowed at the discretion of the investigator and participants parent(s)/ legally acceptable representative (LAR). The N8-GP dose for pre-prophylaxis treatment (except for bleeding episodes) was 60 International unit per kilogram (IU/kg) body weight (within the range of 50-75 IU/kg) to be administered as a single bolus dose intravenously (i.v.) with more than one week between doses (at the discretion of the investigator). Participants who developed FVIII inhibitors in the trial were shifted to ITI treatment.

For prophylaxis treatment, regular N8-GP administration was initiated no later than at the participants age of 24 months, or after 20 EDs on pre-prophylaxis, whatever came first. During the main phase of the trial, participants received prophylaxis with i.v. injections of N8-GP preferably twice weekly, with doses separated by at least 3, and no more than 4, calendar days. Furthermore, it was permissible to start prophylaxis in the main phase with an every 3rd day or once-weekly dosing regimen. The N8-GP dose for prophylaxis treatment was 60 IU/kg (within the range of 50-75 IU/kg) to be administered as a single bolus dose i.v. on each administration day. Participants who developed FVIII inhibitors in the trial were shifted to ITI treatment.

For prophylaxis treatment, regular N8-GP administration was initiated no later than at the participants age of 24 months, or after 20 EDs on pre-prophylaxis, whatever came first. During the main phase of the trial, participants received prophylaxis with i.v. injections of N8-GP preferably twice weekly, with doses separated by at least 3, and no more than 4, calendar days. Furthermore, it was permissible to start prophylaxis in the main phase with an every 3rd day or once-weekly dosing regimen. The N8-GP dose for prophylaxis treatment was 60 IU/kg (within the range of 50-75 IU/kg) to be administered as a single bolus dose i.v. on each administration day. Participants who developed FVIII inhibitors in the trial were shifted to ITI treatment.

At the beginning of the main phase of the trial, slow start prophylaxis and on-demand treatment of bleeding episodes with trial product (Turoctocog alfa pegol (N8-GP)) were allowed at the discretion of the investigator and participants parent(s)/ legally acceptable representative (LAR). The N8-GP dose for pre-prophylaxis treatment (except for bleeding episodes) was 60 International unit per kilogram (IU/kg) body weight (within the range of 50-75 IU/kg) to be administered as a single bolus dose intravenously (i.v.) with more than one week between doses (at the discretion of the investigator). Participants who developed FVIII inhibitors in the trial were shifted to ITI treatment.

For prophylaxis treatment, regular N8-GP administration was initiated no later than at the participants age of 24 months, or after 20 EDs on pre-prophylaxis, whatever came first. During the main phase of the trial, participants received prophylaxis with i.v. injections of N8-GP preferably twice weekly, with doses separated by at least 3, and no more than 4, calendar days. Furthermore, it was permissible to start prophylaxis in the main phase with an every 3rd day or once-weekly dosing regimen. The N8-GP dose for prophylaxis treatment was 60 IU/kg (within the range of 50-75 IU/kg) to be administered as a single bolus dose i.v. on each administration day. Participants who developed FVIII inhibitors in the trial were shifted to ITI treatment.

At the beginning of the main phase of the trial, slow start prophylaxis and on-demand treatment of bleeding episodes with trial product (Turoctocog alfa pegol (N8-GP)) were allowed at the discretion of the investigator and participants parent(s)/ legally acceptable representative (LAR). The N8-GP dose for pre-prophylaxis treatment (except for bleeding episodes) was 60 International unit per kilogram (IU/kg) body weight (within the range of 50-75 IU/kg) to be administered as a single bolus dose intravenously (i.v.) with more than one week between doses (at the discretion of the investigator). Participants who developed FVIII inhibitors in the trial were shifted to ITI treatment.

For prophylaxis treatment, regular N8-GP administration was initiated no later than at the participants age of 24 months, or after 20 EDs on pre-prophylaxis, whatever came first. During the main phase of the trial, participants received prophylaxis with i.v. injections of N8-GP preferably twice weekly, with doses separated by at least 3, and no more than 4, calendar days. Furthermore, it was permissible to start prophylaxis in the main phase with an every 3rd day or once-weekly dosing regimen. The N8-GP dose for prophylaxis treatment was 60 IU/kg (within the range of 50-75 IU/kg) to be administered as a single bolus dose i.v. on each administration day. Participants who developed FVIII inhibitors in the trial were shifted to ITI treatment.

At the beginning of the main phase of the trial, slow start prophylaxis and on-demand treatment of bleeding episodes with trial product (Turoctocog alfa pegol (N8-GP)) were allowed at the discretion of the investigator and participants parent(s)/ legally acceptable representative (LAR). The N8-GP dose for pre-prophylaxis treatment (except for bleeding episodes) was 60 International unit per kilogram (IU/kg) body weight (within the range of 50-75 IU/kg) to be administered as a single bolus dose intravenously (i.v.) with more than one week between doses (at the discretion of the investigator). Participants who developed FVIII inhibitors in the trial were shifted to ITI treatment.

Participants who developed FVIII inhibitors in the trial were offered ITI treatment with N8-GP. If a newly diagnosed inhibitor participant still responded well to treatment with N8-GP, initiation of ITI could be postponed with up to 6 months, or ITI could be cancelled if the inhibitors had resolved during the 6 months. N8-GP treatment could continue in case of low titre FVIII inhibitor (lesser than or equal (≤) 5 Bethesda Units). In case of high titre FVIII inhibitor (greater than (>) 5 Bethesda Units), the investigator had to decide how to proceed with treatment. ITI with N8-GP had to be initiated within 6 months of the confirmatory inhibitor test. The N8-GP dose for ITI treatment was according to local standard. Maximum of 75 IU/kg as single dose, maximum of 200 IU/kg over 24 hours.